Invest now
Piramal Pharma share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹197.35(0.36%)October 12, 2026 15:29:35 PM IST
- NSE
- BSE
- Vol : 1.53 M (NSE + BSE)Last 20 day avg : 3.21 M
Piramal Pharma is trading 0.36% upper at Rs 197.35 as compared to its last closing price. Piramal Pharma has been trading in the price range of 199.00 & 194.90. Piramal Pharma has given 14.33% in this year & -0.55% in the last 5 days. There are 9 analysts who have initiated coverage on Piramal Pharma. There are 5 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of -69.39 Crores in its last quarter.Listed peers of Piramal Pharma include Sun Pharmaceutical Industries (0.13%), Divi's Laboratories (0.57%), Torrent Pharmaceuticals (0.41%).The Mutual Fund holding in Piramal Pharma was at 13.18% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Piramal Pharma was at 12.51% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 12 Oct 2026, 05:51 PM IST
- BetaHigh volatility1.37Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.70The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Piramal Pharma News
Piramal Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,759.10 | 0.13 | 4,22,057.07 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,379.00 | 0.57 | 2,48,982.98 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,679.00 | 0.41 | 1,77,967.75 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,313.70 | 0.80 | 1,06,128.36 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,139.00 | 2.14 | 1,13,615.69 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allPiramal Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-29 | Quarterly Results |
| 2026-04-28 | Audited Results |
| 2026-01-28 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
| 2025-07-28 | Quarterly Results |
About the company Piramal Pharma
- IndustryBiotechnology & Drugs
- ISININE0DK501011
- BSE Code543635
- NSE CodePPLPHARMA
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
Piramal Pharma Share Price FAQs
Piramal Pharma is trading at 197.35 as on Mon Oct 12 2026 09:59:35. This is 0.36% upper as compared to its previous closing price of 196.65.
The market capitalization of Piramal Pharma is 26274.16 Cr as on Mon Oct 12 2026 09:59:35.
The average broker rating on Piramal Pharma is Strong Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Piramal Pharma is 231.85 whereas the 52 wk low is 132.50
Piramal Pharma can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 34.46
- Dividend Yield: 0.00%
- D/E ratio: -
Piramal Pharma reported a net profit of -325.94 Cr in 2026.
The Mutual Fund Shareholding was 13.18% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Piramal Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.